Nanobodies: new avenue to treat kidney disease

9Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Current therapeutic options for renal diseases are limited, and the search for disease-specific treatments is ongoing. Nanobodies, single-domain antibodies with many advantages over conventional antibodies, provide flexible, easy-to-format biologicals with many possible applications. Here, we discuss the potential use of nanobodies for renal diseases.

Cite

CITATION STYLE

APA

Wanner, N., Eden, T., Liaukouskaya, N., & Koch-Nolte, F. (2021, August 1). Nanobodies: new avenue to treat kidney disease. Cell and Tissue Research. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00441-021-03479-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free